More moderate dose escalation, higher protein targets, mandatory resistance training, and potentially shorter treatment courses with emphasis on maintenance dosing may be appropriate
This is not about intense exercise
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Marys Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea 2 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea Corresponding author: Soo Lim
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Beyond product access, strong supply relationships contribute to smoother planning and improved operational consistency